Extrapyramidal	extrapyramidal	O	S_disease
side	side	O	B_disease
effects	effects	O	I_disease
with	with	O	O
risperidone	risperidone	O	O
and	and	O	O
haloperidol	haloperidol	O	O
at	at	O	O
comparable	comparable	O	O
D2	d2	S_chemicals	O
receptor	receptor	O	O
occupancy	occupancy	O	O
levels	levels	O	O
.	.	O	O

Risperidone	risperidone	O	O
is	is	O	O
an	an	O	O
antipsychotic	antipsychotic	B_chemicals	O
drug	drug	S_chemicals	O
with	with	O	O
high	high	O	O
affinity	affinity	O	O
at	at	O	O
dopamine	dopamine	B_chemicals	O
D2	d2	S_chemicals	O
and	and	O	O
serotonin	serotonin	B_chemicals	O
5-HT2	5-ht2	I_chemicals	O
receptors	receptors	I_chemicals	O
.	.	O	O

Previous	previous	O	O
clinical	clinical	O	O
studies	studies	O	O
have	have	O	O
proposed	proposed	O	O
that	that	O	O
risperidone	risperidone	O	O
's	's	O	O
pharmacologic	pharmacologic	O	O
profile	profile	O	O
may	may	O	O
produce	produce	O	O
improved	improved	O	O
efficacy	efficacy	O	O
for	for	O	O
negative	negative	O	O
psychotic	psychotic	O	O
symptoms	symptoms	O	O
and	and	O	O
decreased	decreased	O	O
propensity	propensity	O	O
for	for	O	O
extrapyramidal	extrapyramidal	O	S_disease
side	side	O	B_disease
effects	effects	O	I_disease
;	;	O	O
features	features	O	O
shared	shared	O	O
by	by	O	O
so-called	so-called	O	O
'	'	O	O
atypical	atypical	O	O
'	'	O	O
neuroleptics	neuroleptics	S_chemicals	O
.	.	O	O

To	to	O	O
determine	determine	O	O
if	if	O	O
routine	routine	O	O
risperidone	risperidone	O	O
treatment	treatment	O	O
is	is	O	O
associated	associated	O	O
with	with	O	O
a	a	O	O
unique	unique	O	O
degree	degree	O	O
of	of	O	O
D2	d2	S_chemicals	O
receptor	receptor	O	O
occupancy	occupancy	O	O
and	and	O	O
pattern	pattern	O	O
of	of	O	O
clinical	clinical	O	O
effects	effects	O	O
,	,	O	O
we	we	O	O
used	used	O	O
[123I]IBZM	[123i]ibzm	O	O
SPECT	spect	O	O
to	to	O	O
determine	determine	O	O
D2	d2	S_chemicals	O
occupancy	occupancy	O	O
in	in	O	O
subjects	subjects	O	O
treated	treated	O	O
with	with	O	O
routine	routine	O	O
clinical	clinical	O	O
doses	doses	O	O
of	of	O	O
risperidone	risperidone	O	O
(	(	O	O
n	n	O	O
=	=	O	O
12	12	O	O
)	)	O	O
or	or	O	O
haloperidol	haloperidol	O	O
(	(	O	O
n	n	O	O
=	=	O	O
7	7	O	O
)	)	O	O
.	.	O	O

Both	both	O	O
risperidone	risperidone	O	O
and	and	O	O
haloperidol	haloperidol	O	O
produced	produced	O	O
D2	d2	S_chemicals	O
occupancy	occupancy	O	O
levels	levels	O	O
between	between	O	O
approximately	approximately	O	O
60	60	O	O
and	and	O	O
90	90	O	O
%	%	O	O
at	at	O	O
standard	standard	O	O
clinical	clinical	O	O
doses	doses	O	O
.	.	O	O

There	there	O	O
was	was	O	O
no	no	O	O
significant	significant	O	O
difference	difference	O	O
between	between	O	O
occupancy	occupancy	O	O
levels	levels	O	O
obtained	obtained	O	O
with	with	O	O
haloperidol	haloperidol	O	O
or	or	O	O
risperidone	risperidone	O	O
.	.	O	O

Drug-induced	drug-induced	O	S_disease
parkinsonism	parkinsonism	O	S_disease
was	was	O	O
observed	observed	O	O
in	in	O	O
subjects	subjects	O	O
treated	treated	O	O
with	with	O	O
risperidone	risperidone	O	O
(	(	O	O
42	42	O	O
%	%	O	O
)	)	O	O
and	and	O	O
haloperidol	haloperidol	O	O
(	(	O	O
29	29	O	O
%	%	O	O
)	)	O	O
and	and	O	O
was	was	O	O
observed	observed	O	O
at	at	O	O
occupancy	occupancy	O	O
levels	levels	O	O
above	above	O	O
60	60	O	O
%	%	O	O
.	.	O	O

Based	based	O	O
on	on	O	O
these	these	O	O
observations	observations	O	O
,	,	O	O
it	it	O	O
is	is	O	O
concluded	concluded	O	O
that	that	O	O
5-HT2	5-ht2	O	O
blockade	blockade	O	O
obtained	obtained	O	O
with	with	O	O
risperidone	risperidone	O	O
at	at	O	O
D2	d2	S_chemicals	O
occupancy	occupancy	O	O
rates	rates	O	O
of	of	O	O
60	60	O	O
%	%	O	O
and	and	O	O
above	above	O	O
does	does	O	O
not	not	O	O
appear	appear	O	O
to	to	O	O
protect	protect	O	O
against	against	O	O
the	the	O	O
risk	risk	O	O
for	for	O	O
extrapyramidal	extrapyramidal	O	S_disease
side	side	O	B_disease
effects	effects	O	I_disease
.	.	O	O

